PReCedeNT trial: Phase III randomized-controlled trial of Lutetium − 177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) plus Chemotherapy versus PRRT alone in FDG-avid, Well-differentiated Gastroenteropancreatic neuroendocrine tumors (GEP-NETs
This trial is registered with the Clinical Trials Registry of India (CTRI/2019/07/027255) and ClinicalTrials.gov ID: NCT07185672.
Authors
- Vikram Chaudhari (ORCID: https://orcid.org/0000-0001-8033-0277)
- Archi Agrawal (ORCID: https://orcid.org/0000-0003-1608-7780)
- Rahul V. Parghane
- Prabhat Bhargava (ORCID: https://orcid.org/0000-0002-6440-2186)
- V. Manikandan
- Ameya D. Puranik (ORCID: https://orcid.org/0000-0001-6125-992X)
- Indraja D. Dev (ORCID: https://orcid.org/0000-0003-3922-4100)
- Sushil Yadav
- Shailesh V. Shrikhande (ORCID: https://orcid.org/0000-0002-8036-4212)
- Sandip Kanti Basu (ORCID: https://orcid.org/0000-0001-6607-2558)
- Sayak Choudhury (ORCID: https://orcid.org/0000-0002-0610-0761)
- Vikas S Ostwal (ORCID: https://orcid.org/0000-0002-0067-4748)
- Subhash Yadav (ORCID: https://orcid.org/0000-0003-1116-6930)
- Munita Bal (ORCID: https://orcid.org/0000-0002-0345-5620)
- Manish Bhandare (ORCID: https://orcid.org/0000-0002-5390-130X)
- Nilendu Purandare (ORCID: https://orcid.org/0000-0003-0952-0347)
- Suchismita Ghosh
- Sneha Shah (ORCID: https://orcid.org/0000-0002-9654-6694)
- Mahesh Goel
- Shraddha Patkar
- Venkatesh Rangarajan
- Anant Ramaswamy
Institutions
- Homi Bhabha National Institute (IN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1186/s12885-025-15111-x
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00